Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: Comparison of cyclosporine and tacrolimus eras

Transplantation

Volumn 100, Issue 8, 2016, Pages 1723-1731

  Nankivell, Brian J ^a   Ng, Chow H P ^a   O'Connell, Philip J ^a   Chapman, Jeremy R ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTERY BLOOD FLOW; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DOSE RESPONSE; FEMALE; GLOMERULOSCLEROSIS; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYALINE DEGENERATION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TUBULE DAMAGE; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; NEPHROTOXICITY; PRIORITY JOURNAL; ADVERSE EFFECTS; BIOPSY; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; INCIDENCE; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; NEW SOUTH WALES; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURGERY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; BIOPSY; CALCINEURIN INHIBITORS; CYCLOSPORINE; DISEASE PROGRESSION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; NEW SOUTH WALES; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84974852000     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001243     Document Type: Article

References (46)

1. Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int. 1996;50:1089-1100.
2. Mihatsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int Suppl. 1995;52:S63-S69.
3. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc. 1988;20(3 Suppl 3):759-771.
4. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481-508.
5. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation. 1998;66:1736-1740.
6. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl JMed. 2003;349:931-940.
7. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004;78:557-565.
8. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant. 2011;11: 450-462.
9. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713-723.
10. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl JMed. 2003;349:2326-2333.
11. Snanoudj R, Royal V, Elie C, et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under lowdose cyclosporine therapy. Am J Transplant. 2011;11:2635-2646.
12. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272-283.
13. Kuypers DR, NaesensM, de JongeH, et al. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitorassociated nephrotoxicity in renal allograft recipients. Ther Drug Monit. 2010;32:394-404.
14. Knops N, van den Heuvel LP, Masereeuw R, et al. The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells. Mol Pharm. 2015;12:758-768.
15. Gibson IW, Downie TT, More IA, et al. Atubular glomeruli and glomerular cysts-a possible pathway for nephron loss in the human kidney? J Pathol. 1996;179:421-426.
16. Randhawa PS, Shapiro R, Jordan ML, et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol. 1993;17:60-68.
17. Liptak P, Ivanyi B. Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol. 2006;2:398-404.
18. Sharma A, Jain S, Gupta R, et al. Ultrastructural alterations in endothelial mitochondria are associated with enhanced nitrotyrosine accumulation and progressive reduction of VEGF expression in sequential protocol renal allograft biopsies with calcineurin inhibitor toxicity. Transpl Int. 2010;23: 407-416.
19. Bagnis C, Deray G, Dubois M, et al. Comparative acute nephrotoxicity of FK-506 and ciclosporin in an isolated in situ autoperfused rat kidney model. Am J Nephrol. 1997;17:17-24.
20. Klein IH, Abrahams A, van Ede T, et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation. 2002;73:732-735.
21. Nankivell BJ, Chapman JR, Bonovas G, et al. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation. 2004; 77:1457-1459.
22. Benigni A, Bruzzi I, Mister M, et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int. 1999;55:674-685.
23. Jacobson PA, Schladt D, Israni A, et al. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. Transplantation. 2012;93:624-631.
24. Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther. 1996;34:515-519.
25. Rosen S, Greenfeld Z, Brezis M. Chronic cyclosporine-induced nephropathy in the rat. A medullary ray and inner stripe injury. Transplantation. 1990;49:445-452.
26. Kumagai H, Katoh S, Hirosawa K, et al. Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney Int. 2002;62: 1219-1228.
27. Suzuki T, Kimura M, Asano M, et al. Role of atrophic tubules in development of interstitial fibrosis in microembolism-induced renal failure in rat. Am J Pathol. 2001;158:75-85.
28. Satyanarayana PS, Chopra K. Oxidative stress-mediated renal dysfunction by cyclosporine A in rats: attenuation by trimetazidine. Ren Fail. 2002;24:259-274.
29. Bing P, Maode L, Li F, et al. Comparison of expression of TGF-beta1, its receptors TGFbeta1R-I and TGFbeta1R-II in rat kidneys during chronic nephropathy induced by cyclosporine and tacrolimus. Transplant Proc. 2006;38:2180-2182.
30. Esposito C, Foschi A, Parrilla B, et al. Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli. Transplant Proc. 2004;36:695-697.
31. Khanna A. Tacrolimus and cyclosporinein vitro and in vivo induce osteopontin mRNA and protein expression in renal tissues. Nephron Exp Nephrol. 2005;101:e119-e126.
32. Moutabarrik A, Ishibashi M, Fukunaga M, et al. FK506-induced kidney tubular cell injury. Transplantation. 1992;54:1041-1047.
33. Davies DR, Bittmann I, Pardo J. Histopathology of calcineurin inhibitorinduced nephrotoxicity. Transplantation. 2000;69(12 Suppl):SS11-SS13.
34. Kim JY, Suh KS. Light microscopic and electron microscopic features of cyclosporine nephrotoxicity in rats. J Korean Med Sci. 1995;10: 352-359.
35. Baboolal K, Jones GA, Janezic A, et al. Molecular and structural consequences of early renal allograft injury. Kidney Int. 2002;61: 686-696.
36. Roos-van Groningen MC, Scholten EM, Lelieveld PM, et al. Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol. 2006;17: 881-888.
37. Jain S, BicknellGR, NicholsonML. Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. Br J Surg. 2000;87:1563-1568.
38. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357: 2562-2575.
39. Bröcker V, Schubert V, Scheffner I, et al. Arteriolar lesions in renal transplant biopsies: prevalence, progression, and clinical significance. Am J Pathol. 2012;180:1852-1862.
40. First MR, Dhadda S, Croy R, et al. New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. Transplantation. 2013;96:58-64.
41. Kobayashi A, Yamamoto I, Ito S, et al. Medullary ray injury in renal allografts. Pathol Int. 2010;60:744-749.
42. GwinnerW, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant. 2005;5:1934-1941.
43. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation. 2006;81:643-654.
44. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527-535.
45. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study. Am J Transplant. 2010;10:324-330.
46. Montgomery RA. One kidney for life. Am J Transplant. 2014;14: 1473-1474.